UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 66

Sortiert nach

Complementary and alternative medications in the management of inflammatory bowel disease

Therapeutic Advances in Gastroenterology, 2020, Vol.13, p.175628482092755-1756284820927550

2020

Link zum Volltext

Verfügbarkeit prüfen

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Clinical gastroenterology and hepatology, 2016-09, Vol.14 (9), p.1302-1309

2016

Link zum Volltext

Verfügbarkeit prüfen

Defining quality indicators for best-practice management of inflammatory bowel disease in Canada

Canadian journal of gastroenterology & hepatology, 2014-05, Vol.28 (5), p.275-285

2014

Link zum Volltext

Verfügbarkeit prüfen

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clinical gastroenterology and hepatology, 2019-08, Vol.17 (9), p.1655-1668.e3

2019

Link zum Volltext

Verfügbarkeit prüfen

A survey of perceptions and practices of complementary alternative medicine among Canadian gastroenterologists

Canadian journal of gastroenterology & hepatology, 2014-01, Vol.28 (1), p.45-49

2014

Link zum Volltext

Verfügbarkeit prüfen

Colometer：A real-time quality feedback system for screening colonoscopy

World journal of gastroenterology : WJG, 2012-08, Vol.18 (32), p.4270-4277

2012

Link zum Volltext

Verfügbarkeit prüfen

Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up

Gastroenterology clinics of North America, 2009-12, Vol.38 (4), p.577

2009

Link zum Volltext

Verfügbarkeit prüfen

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study

Inflammatory bowel diseases, 2017-05, Vol.23 (5), p.833-839

2017

Link zum Volltext

Verfügbarkeit prüfen

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease

Gastroenterology clinics of North America, 2012-06, Vol.41 (2), p.411

2012

Link zum Volltext

Verfügbarkeit prüfen

Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease

Alimentary pharmacology & therapeutics, 2018-09, Vol.48 (6), p.626-637

2018

Link zum Volltext

Verfügbarkeit prüfen

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy

Canadian journal of gastroenterology, 2004-05, Vol.18 (5), p.321

2004

Link zum Volltext

Verfügbarkeit prüfen

Do thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease or is this an unanswerable question?

Inflammatory bowel diseases, 2012-06, Vol.18 (6), p.1184-1185

Devlin, Shane M.

2012

Link zum Volltext

Verfügbarkeit prüfen

Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All

Clinical gastroenterology and hepatology, 2018-11, Vol.16 (11), p.1829-1831

2018

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel

Inflammatory bowel diseases, 2016-06, Vol.22 (6), p.1418-1424

2016

Link zum Volltext

Verfügbarkeit prüfen

Appropriateness of Concomitant Immunomodulator and Biologic Therapy in Crohn’s Disease and Ulcerative Colitis

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S590-S590

2017

Link zum Volltext

Verfügbarkeit prüfen

Preoperative Ustekinumab Treatment is not Associated with Increased Postoperative Complications in crohn's Disease: A Canadian Multicentre Case–Control Cohort Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S577-S577

2017

Link zum Volltext

Verfügbarkeit prüfen

Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study

Gastroenterology (New York, N.Y. 1943), 2017-04, Vol.152 (5), p.S410-S411

2017

Link zum Volltext

Verfügbarkeit prüfen

NOD2 Variants and Antibody Response to Microbial Antigens in Crohn’s Disease Patients and Their Unaffected Relatives

Gastroenterology (New York, N.Y. 1943), 2007-02, Vol.132 (2), p.576-586

2007

Link zum Volltext

Verfügbarkeit prüfen

The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All

Clinical gastroenterology and hepatology, 2010-08, Vol.8 (8), p.655-659

2010

Link zum Volltext

Verfügbarkeit prüfen

Curry for the cure?

Inflammatory bowel diseases, 2007-12, Vol.13 (12), p.1576-1577

Devlin, Shane M.

2007

Link zum Volltext

Verfügbarkeit prüfen

1055 Recommendations for Creating a High Quality Endoscopy Report for Inflammatory Bowel Disease Patients: Results From a RAND-Appropriateness Panel

Gastroenterology (New York, N.Y. 1943), 2014-05, Vol.146 (5), p.S-188-S-188

2014

Link zum Volltext

Verfügbarkeit prüfen

Assessment of Variables Associated with Smoking Cessation in Crohn’s Disease

Digestive diseases and sciences, 2012-04, Vol.57 (4), p.1026-1032

2012

Link zum Volltext

Verfügbarkeit prüfen

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

Canadian journal of gastroenterology, 2013-10, Vol.27 (10), p.567

2013

Link zum Volltext

Verfügbarkeit prüfen

Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD

Inflammatory bowel diseases, 2008-01, Vol.14 (1), p.125-128

2008

Link zum Volltext

Verfügbarkeit prüfen

Mucormycosis presenting as recurrent gastric perforation in a patient with crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy

Digestive diseases and sciences, 2007-09, Vol.52 (9), p.2078-2081

2007

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 66

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(56)

Publikationsform

Sprache

Englisch
(66)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(35)
Humans
(28)
Gastroenterology & Hepatology
(26)
Crohn's Disease
(13)
Gastroenterology And Hepatology
(13)
Inflammatory Bowel Disease
(13)
Male
(12)
Ulcerative Colitis
(12)
Adult
(9)
Aged
(8)
Female
(8)
Middle Aged
(8)
Gastroenterology
(7)
Original
(6)
Treatment Outcome
(6)
Antibodies, Monoclonal - Therapeutic Use
(5)
Crohn Disease
(5)
Crohn Disease - Drug Therapy
(5)
Immunosuppressive Agents - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Complementary and alternative medications in the management of inflammatory bowel disease

Appropriateness of Testing for Anti–Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results

Defining quality indicators for best-practice management of inflammatory bowel disease in Canada

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

A survey of perceptions and practices of complementary alternative medicine among Canadian gastroenterologists

Colometer：A real-time quality feedback system for screening colonoscopy

Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up

Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study

Patient-specific approach to combination versus monotherapy with the use of antitumor necrosis factor α agents for inflammatory bowel disease

Real‐world clinical, endoscopic and radiographic efficacy of vedolizumab for the treatment of inflammatory bowel disease

Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy

Do thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease or is this an unanswerable question?

Appropriateness of Combination Therapy for Patients With Inflammatory Bowel Diseases: One Size Still Does Not Fit All

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel

Appropriateness of Concomitant Immunomodulator and Biologic Therapy in Crohn’s Disease and Ulcerative Colitis

Preoperative Ustekinumab Treatment is not Associated with Increased Postoperative Complications in crohn's Disease: A Canadian Multicentre Case–Control Cohort Study

Ustekinumab is Effective for Inducing Clinical, Endoscopic, and Radiographic Response and Remission in Refractory Moderate-to-Severe Crohn's Disease: A Multicentre Cohort Study

NOD2 Variants and Antibody Response to Microbial Antigens in Crohn’s Disease Patients and Their Unaffected Relatives

The Appropriateness of Concomitant Immunomodulators With Anti–Tumor Necrosis Factor Agents for Crohn's Disease: One Size Does Not Fit All

Curry for the cure?

1055 Recommendations for Creating a High Quality Endoscopy Report for Inflammatory Bowel Disease Patients: Results From a RAND-Appropriateness Panel

Assessment of Variables Associated with Smoking Cessation in Crohn’s Disease

Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics

Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD

Mucormycosis presenting as recurrent gastric perforation in a patient with crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy

Suchergebnisse filtern